Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Archives of Psychiatry and Clinical Neuroscience
Published in: European Archives of Psychiatry and Clinical Neuroscience 3/2016

Open Access 01-04-2016 | Original Paper

A retrospective classification of diagnoses in terms of DSM-5 for patients included in randomized controlled trials of Ginkgo biloba extract EGb 761®

Authors: Robert Hoerr, Michael Zaudig

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 3/2016

Login to get access

Abstract

When the early trials of Ginkgo biloba extract EGb 761® were conducted, different terms were used to denote ageing-associated neurocognitive disorders. With the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), a taxonomy covering dementia and pre-dementia stages of such disorders became available. DSM-5 diagnostic criteria for neurocognitive disorders (NCDs) were applied to patients with any type of ageing-associated cognitive impairment, including dementia, enrolled in randomized controlled clinical trials of EGb 761®, taking into account the reported inclusion and exclusion criteria and patient characteristics at baseline. For 23 of 31 trials (74 %), the inclusion diagnoses could be classified as NCD in accordance with DSM-5. Thirteen trials enrolled patients with major NCD, four trials enrolled patients with mild NCD and six trials enrolled patients with NCD, who could not be classified unambiguously as having mild or major NCD. Although various terms were formerly used for neurocognitive disorders, the patients enrolled in the majority of clinical trials with EGb 761® could be classified retrospectively using modern DSM-5 diagnostic criteria.
Appendix
Available only for authorised users
Literature
1.
Levy R, Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization (1994) Report: aging-associated cognitive decline. Int Psychogeriatr 6:63–68CrossRefPubMed
2.
Ebly EM, Hogan DB, Parhad IM (1995) Cognitive impairment in the nondemented elderly: results from the Canadian study of health and aging. Arch Neurol 52:612–619CrossRefPubMed
3.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EF, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308CrossRefPubMed
4.
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, De Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, Van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256:240–246CrossRefPubMed
5.
American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders, 3rd edn. American Psychiatric Association, Washington, DC
6.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944CrossRefPubMed
7.
Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, Moody DM, O’Brien MD, Yamaguchi T, Grafman J, Drayer BP, Bennett DA, Fischer M, Ogata J, Kokmen E, Bermejo F, Wolf PA, Gorelick PB, Bick KL, Pajeau AK, Bell MA, DeCarli C, Culebras A, Korczyn AD, Bogousslavsky J, Hartmann A, Scheinberg P (1993) Vascular dementia: diagnostic criteria for research studies: Report of the NINDS-AIREN International Workshop. Neurology 43:250–260CrossRefPubMed
8.
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn. American Psychiatric Association, Washington
9.
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington
10.
World Health Organization (1992) International statistical classification of diseases and related health problems: tenth revision. World Health Organization, Geneva
11.
Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746CrossRefPubMed
12.
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Arlington
13.
Kurz AF, Lautenschlager NT (2010) The concept of dementia: retain, reframe, rename or replace? Int Psychogeriatr 22:37–42CrossRefPubMed
14.
Gavrilova SI, Preuss UW, Wong JWM, Hoerr R, Kaschel R, Bachinskaya N, GIMCIPlus Study Group (2014) Efficacy and safety of Ginkgo biloba extract EGb 761® in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. Int J Geriatr Psychiatry 29:1087–1095. doi:10.​1002/​gps.​4103 CrossRefPubMed
15.
European Medicines Agency (2014) Community herbal monograph on Ginkgo biloba L., folium: draft. European Medicines Agency, London
16.
Gauthier S, Schlaefke S (2014) Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging 9:2065–2077CrossRefPubMedPubMedCentral
17.
18.
Hoerr NL, Osol A (eds) (1952) Blakiston’s illustrated pocket medical dictionary. McGraw-Hill, New York
19.
20.
McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7:263–269CrossRef
21.
Nikolova G, Yancheva S, Raychev I, Hoerr R, PLAGIN Study Group (2013) Ginkgo biloba extract in dementia: a 22-week randomized, placebo-controlled double-blind trial. Bulg Neurol 14:139–143
22.
Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S (2012) Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomized, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res 46:716–723CrossRefPubMed
23.
Ihl R, Bachinskaya N, Korczyn AD, Vakhapova V, Tribanek M, Hoerr R, Napryeyenko O, GOTADAY Study Group (2011) Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry 26:1186–1194. doi:10.​1002/​gps.​2662 PubMed
24.
Napryeyenko O, Borzenko I, GINDEM-NP Study Group (2007) Ginkgo biloba special extract in dementia with neuropsychiatric features: a randomized, placebo-controlled, double-blind clinical trial. Arzneim Forsch/Drug Res 57:4–11
25.
Yancheva S, Ihl R, Nikolova G, Panayotov P, Schlaefke S, Hoerr R, GINDON Study Group (2009) Ginkgo biloba extract EGb 761®, donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health 13:183–190CrossRefPubMed
26.
Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M (2005) A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res 2:541–551CrossRefPubMed
27.
Maurer K, Ihl R, Dierks T, Frölich L (1997) Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res 31:645–655CrossRefPubMed
28.
Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF, North American EGb Study Group (1997) A placebo-controlled, double-blind randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278:1327–1332CrossRefPubMed
29.
Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R (1996) Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 29:47–56CrossRefPubMed
30.
Rai GS, Shovlin C, Wesnes KA (1991) A double-blind placebo-controlled study of Ginkgo biloba extract (“Tanakan”) in elderly outpatients with mild to moderate memory impairment. Curr Med Res Opin 12:350–355CrossRefPubMed
31.
Haase J, Halama P, Hörr R (1996) Efficacy of short-term treatment with intravenously administered Ginkgo biloba special extract EGb 761 in Alzheimer type and vascular dementia. Z Gerontol Geriatrie 29:302–309
32.
Weitbrecht WU, Jansen W (1986) Primär degenerative Demenz: therapie mit Ginkgo-biloba—Extrakt placebokontrollierte doppelblind–und vergleichsstudie. Fortschr Med 104:199–202PubMed
33.
Oswald WD, Hörr R, Oswald B, Steger W, Sappa J (1997) Zur Verbesserung fluider, kognitiver Leistungen mit Ginkgo-biloba-Spezialextrakt EGb 761® bei Patienten mit leichten bis mittel-schweren Hirnleistungsstörungen im Alter. Z Gerontopsychol Psychiatrie 3:133–146
34.
Gräßel E (1992) Einfluß von Ginkgo-biloba-Extrakt auf die geistige Leistungsfähigkeit. Fortschr Med 110:73–76PubMed
35.
Halama P, Bartsch G, Meng G (1988) Hirnleistungsstörungen vaskulärer Genese: Randomisierte Doppelblindstudie zur Wirksamkeit von Ginkgo–biloba–Extrakt. Fortschr Med 106:408–412PubMed
36.
Hofferberth B (1994) The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol 9:215–222CrossRef
37.
Schubert H, Halama P (1993) Primär therapieresistente depressive verstimmung älterer patienten mit hirnleistungsstörungen: Wirksamkeit der Kombination von Ginkgo-biloba-Extrakt EGb 761 mit Antidepressiva. Geriatr Forsch 3:45–53
38.
Israël L, Dell’Accio E, Martin G, Hugonot R (1987) Extrait de Ginkgo biloba et exercises d’entrainement de la mémoire. Psychol Méd 19:1431–1439
39.
Wesnes K, Simmons D, Rook M, Simpson P (1987) A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly. Hum Psychopharmacol 2:159–169CrossRef
40.
Grass-Kapanke B, Busmane A, Lasmanis A, Hoerr R, Kaschel R (2011) Effects of Ginkgo biloba special extract EGb 761® in very mild cognitive impairment (vMCI). Neurosci Med 2:48–56CrossRef
41.
Allain H, Raoul P, Lieury A, LeCoz F, Gandon JM (1993) Effect of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther 15:549–558PubMed
42.
Stocksmeier U, Eberlein M (1992) Depressive verstimmung bei hirnleistungsstörungen: wirkung eines Ginkgo-biloba—extraktes in doppelblind–studie überprüft. TW Neurol Psychiatr 6:74–76
43.
van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P (2003) Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol 56:367–376CrossRefPubMed
44.
Hofferberth B (1991) Simultanerfassung elektrophysiologischer, psychometrischer und rheologischer Parameter bei Patienten mit hirnorganischem Psychosyndrom und erhöhtem Gefäßrisiko—Eine placebokontrollierte Doppelblindstudie mit Ginkgo-biloba-Extrakt EGb 761. In: Stodtmeister R, Pillunat LE (eds) Mikrozirkulation in Gehirn und Sinnesorganen. Enke, Stuttgart, pp 64–74
45.
Halama P (1990) Therapie mit Ginkgo biloba bei patienten mit cerebrovaskulärer insuffizienz und therapieresistenter depressiver symptomatik: Was leistet der Spezialextrakt (EGb 761)? Therpiewoche 40:3760–3765
46.
Hofferberth B (1989) Einfluß von Ginkgo biloba-Extrakt auf neurophysiologische und psychometrische Messergebnisse bei Patienten mit hirnorganischem Psychosyndrom: Eine Doppelblindstudie gegen Placebo. Arzneim Forsch/Drug Res 39:918–922
47.
Taillandier J, Ammar A, Rabourdin JP, Ribeyre JP, Pichon J, Niddam S, Pierart H (1986) Traitement des troubles du vieillissement cérébral par l’extrait de Ginkgo biloba: Etude longitudinale multicentrique à double insu face au placebo. Presse Méd 15:1583–1587PubMed
48.
Eckmann F, Schlag H (1982) Kontrollierte Doppelblind-Studie zum Wirksamkeitsnachweis von Tebonin forte bei Patienten mit zerebrovaskulärer Insuffizienz. Fortschr Med 100:1474–1478PubMed
49.
Dieli G, LaMantia V, Saetta M, Constanzo E (1981) Studio clinico in doppio cieco del Tanakan nell’ insufficienza cerebrale cronica. Lav Neuropsychiatr 68:3–15
50.
Moreau P (1975) Un nouveau stimulant circulatoire cérébral. Nouv Presse Méd 4:2401–2402PubMed
Metadata
Title
A retrospective classification of diagnoses in terms of DSM-5 for patients included in randomized controlled trials of Ginkgo biloba extract EGb 761®
Authors
Robert Hoerr
Michael Zaudig
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Psychiatry and Clinical Neuroscience / Issue 3/2016
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-015-0632-y

Other articles of this Issue 3/2016

European Archives of Psychiatry and Clinical Neuroscience 3/2016 Go to the issue

Short Communication

Increased daylight availability reduces length of hospitalisation in depressive patients

Original Paper

Clinical significance of psychiatric comorbidity in children and adolescents with obsessive–compulsive disorder: subtyping a complex disorder

Short Communication

CACNA1C risk variant is associated with increased amygdala volume

Original Paper

Altered functional connectivity density in major depressive disorder at rest

Original Paper

Are morphological changes necessary to mediate the therapeutic effects of electroconvulsive therapy?

Original Paper

Decreased ribosomal DNA transcription in dorsal raphe nucleus neurons differentiates between suicidal and non-suicidal death